By contrast, a 89Zr-atezolizumab study in patients with bladder cancer, non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC) reported that pretreatment immunoPET uptake correlated more strongly with clinical outcomes than PD-L1 IHC or RNA-sequencing based gene signatures, with higher tracer uptake predicting improved progression-free and overall survival (50). Here, CD274 is linked to triple-negative breast carcinoma.